Xu YP - Search Results

1

Anti-tumour clerodane-type diterpenes from Mitrephora thorelii.

Meng DH, Xu YP, Chen WL, Zou J, Lou LG, Zhao WM. Meng DH, et al. Among authors: xu yp. J Asian Nat Prod Res. 2007 Sep-Dec;9(6-8):679-84. doi: 10.1080/10286020601103270. J Asian Nat Prod Res. 2007. PMID: 17943565

2

(5R)-5-hydroxytriptolide (LLDT-8), a novel immunosuppressant in clinical trials, exhibits potent antitumor activity via transcription inhibition.

Wang L, Xu Y, Fu L, Li Y, Lou L. Wang L, et al. Cancer Lett. 2012 Nov 1;324(1):75-82. doi: 10.1016/j.canlet.2012.05.004. Epub 2012 May 9. Cancer Lett. 2012. PMID: 22579805

3

A novel and simple hollow-fiber assay for in vivo evaluation of nonpeptidyl thrombopoietin receptor agonists.

Xie CY, Xu YP, Zhao HB, Lou LG. Xie CY, et al. Among authors: xu yp. Exp Hematol. 2012 May;40(5):386-92. doi: 10.1016/j.exphem.2012.01.010. Epub 2012 Jan 21. Exp Hematol. 2012. PMID: 22269115 Free article.

4

Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.

Xie CY, Xu YP, Jin W, Lou LG. Xie CY, et al. Among authors: xu yp. Anticancer Drugs. 2012 Aug;23(7):698-705. doi: 10.1097/CAD.0b013e328352cc10. Anticancer Drugs. 2012. PMID: 22441567

5

p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4.

Quan H, Xu Y, Lou L. Quan H, et al. Int J Cancer. 2008 Apr 15;122(8):1730-7. doi: 10.1002/ijc.23262. Int J Cancer. 2008. PMID: 18074350

6

YHHU0895, a novel synthetic small-molecule microtubule-destabilizing agent, effectively overcomes P-glycoprotein-mediated tumor multidrug resistance.

Zhao H, Quan H, Xie C, Xu Y, Xie F, Hu Y, Lou L. Zhao H, et al. Cancer Lett. 2012 Jan 1;314(1):54-62. doi: 10.1016/j.canlet.2011.09.013. Epub 2011 Sep 19. Cancer Lett. 2012. PMID: 21982683

7

Design, synthesis and anticancer activity of diam(m)ine platinum(II) complexes bearing a small-molecular cell apoptosis inducer dichloroacetate.

Liu W, Jiang J, Xu Y, Hou S, Sun L, Ye Q, Lou L. Liu W, et al. J Inorg Biochem. 2015 May;146:14-8. doi: 10.1016/j.jinorgbio.2015.02.002. Epub 2015 Feb 12. J Inorg Biochem. 2015. PMID: 25706321

8

Y-632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo.

Wang W, Liu Y, Zhao Z, Xie C, Xu Y, Hu Y, Quan H, Lou L. Wang W, et al. Cancer Sci. 2016 Jun;107(6):782-90. doi: 10.1111/cas.12934. Epub 2016 Apr 27. Cancer Sci. 2016. PMID: 27002306 Free PMC article.

9

Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.

Wang H, Wang W, Xu Y, Yang Y, Chen X, Quan H, Lou L. Wang H, et al. Cancer Sci. 2017 Jul;108(7):1458-1468. doi: 10.1111/cas.13253. Epub 2017 May 23. Cancer Sci. 2017. PMID: 28388007 Free PMC article.

10

Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia.

Xie C, He Y, Zhen M, Wang Y, Xu Y, Lou L. Xie C, et al. Cancer Sci. 2017 Jul;108(7):1476-1484. doi: 10.1111/cas.13263. Epub 2017 May 23. Cancer Sci. 2017. PMID: 28418085 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

504 results

Search Page

Filters